About Saxenda Injectable Pens
(See the Original Document Here)
What is Type 2 Diabetes? When a person has type 2 diabetes, body cells become resistant to insulin. As a result, your body makes more insulin to get cells to respond. This imbalance in your blood sugar may lead to type 2 diabetes. High blood sugar can cause serious health problems causing amputation or affecting your heart, vision, and kidneys.
What is Type 1 diabetes? Type 1 diabetes is an immune system disorder in which the body cannot make insulin or the body produces insulin in a tiny amount.
Saxenda Injectable Pens contains liraglutide, an analog of human insulin. This type of insulin uses DNA technology in Saccharomyces cerevisiae. GLP-1 acts as a GLP-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes expression of recombinant DNA in Saccharomyces cerevisiae, is engineered to be 97% homologous to native human GLP-1. It is a clear, colorless solution. Each 1 mL of SAXENDA solution contains 6 mg of liraglutide. Each pre-filled pen of 3 mL solution contains a total of 18 mg liraglutide (free-base, anhydrous). Liraglutide is a long-acting Glucagon-like Peptide-1 (GLP-1) receptor agonist. Liraglutide inside Saxenda Injectable Pens is a long-acting GLP-1 receptor agonist. It will release more insulin in the blood as the blood glucose increases, and insulin release decreases as the demand for insulin in the body reduces.
Glucagon-like peptide-1 (GLP-1) receptor works in three ways to control blood glucose.
- It helps the body produce more insulin.
- It helps slow down the liver’s release of sugar into the bloodstream.
- It slows the rate at which food leaves your stomach and passes into the intestine.
Warning while using Saxenda Injectable Pens
For Saxenda Injectable Pens 6 Mg/m, some risks associated with this type of medicine are listed below:
- Risk of Thyroid C-Cell Tumours
- Breast neoplasms
- Cardiovascular
- Endocrine and Metabolism
- Hypoglycemia
- Hepatic/Biliary/Pancreatic
- Acute Gallbladder Disease
- Immune
- Hypersensitivity Reactions
- Psychiatric
- Suicidal Behavior and Ideation
Other precautions while using Saxenda Injectable Pens
- Pregnant Women – Do not use SAXENDA during pregnancy.
- Breastfeeding – Women who are nursing.
- Should discontinue SAXENDA treatment.
- Pediatrics – Can be used for children between 12 and 18 years.
- Geriatrics – Patients above 65 years may experience gastrointestinal side effects.
- Cardiovascular – SAXENDA should be used cautiously in patients with recent myocardial infarction, unstable angina, and congestive heart failure.
- Hepatic Insufficiency – SAXENDA is not recommended.
- Renal Insufficiency – Use caution when initiating or escalating doses of Saxenda.
Gastrointestinal Disorders may include:
- Nausea
- Diarrhea
- Constipation
- Vomiting
- Dyspepsia
- Abdominal Pain
- Abdominal Pain Upper
- Abdominal distension
- Eructation
- Flatulence
- Gastroesophageal Reflux Disease
- Dry Mouth
- Gastritis
Symptoms of Hypoglycaemia may include:
- dizziness or lightheartedness
- blurred vision
- anxiety, irritability, or mood changes
- sweating
- slurred speech
- hunger
- confusion or drowsiness
- shakiness
- weakness
- headache
- fast heartbeat
- feeling jittery
What is the dosage of Saxenda Injectable Pens
- Do not use Saxenda and Victoza together, as they have a common ingredient.
- SAXENDA and Victoza are not a substitute for each other.
- Do not take SAXENDA with another insulin.
- For Patients with Type 2 Diabetes Mellitus: Do not combine SAXENDA with another GLP-1 receptor agonist.
- SAXENDA is not a substitute for insulin.
- If you discontinue SAXENDA in patients with type 2, you may observe an increase in blood glucose.
In adults with an initial BMI of 27 kg/m2 or greater, the recommended daily maintenance dose is 3.0 mg/day. Daily doses higher than 3.0 mg are not recommended.
How to store Saxenda Injectable Pens?
Store Saxenda Injectable Pens in a refrigerator (2ºC to 8ºC). Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze SAXENDA®, and do not use SAXENDA® if it is ever frozen. After initial use of the Saxenda Injectable Pens, the product can be stored for 30 days at room temperature (not above 30°C) or in a refrigerator (2°C to 8°C).
Unused: Store in a refrigerator (2ºC to 8ºC). Do not freeze. Discard Saxenda Injectable Pens if frozen.
Used: Until expiry or a maximum of 30 days at room temperature (not above 30°C) or in a refrigerator (2°C to 8°C).
